{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 76,
  "pageCount": 366,
  "prevPage": 75,
  "nextPage": 77,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses excerpts from scientific literature to frame the technical hurdles in CNS drug development.",
  "elementsJson": [
    "paragraph",
    "bullet_list",
    "screenshot"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/76",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-76",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Another paper highlighted how these issues plague non-imidazole-based compounds specifically, such as pitolisant: “poor pharmacokinetic characteristics,” “poor blood-brain penetration,” “genotoxicity” (DNA damage), as well as the problems such as cardiotoxicity already described on previous pages.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cce-da46c86e5060",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.41,
        "x": 0.52,
        "y": 0.55
      },
      "kind": "list",
      "text": "phospholipidosis; interactions with the hERG potassium channel; high plasma protein binding; poor blood-brain penetration; genotoxicity; high lipophilicity; poor pharmacokinetic (PK) characteristics; CYP450 interactions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d7cce2d-f99c-4e22-ab2e-4a95492755a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "The paper attributes “one of the challenges with H3R receptor antagonist design” as being the “similarity between the H3 and hERG pharmacophores.” Another paper highlighted how these issues plague non-imidazole-based compounds specifically, such as pitolisant: “poor pharmacokinetic characteristics,” “poor blood-brain penetration,” “genotoxicity” (DNA damage), as well as the problems such as cardiotoxicity already described on previous pages.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08c60f35-dd7a-46ac-8b37-60e21b738ed5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.41,
        "x": 0.52,
        "y": 0.37
      },
      "kind": "paragraph",
      "text": "Recent advances in histamine H3 receptor antagonists/inverse agonists of unwanted effects. Some of the hurdles described for the non-imidazole H3R antagonists are:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33d767a1-85a2-4d2f-95c4-ddc0a271fe40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.41,
        "x": 0.07,
        "y": 0.37
      },
      "kind": "paragraph",
      "text": "The histamine H3 receptor as a therapeutic drug target for CNS disorders. As discussed above, one of the challenges with H3R antagonist design is overcoming the similarity between the H3 and hERG pharmacophores...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d43d5ae7-df83-4622-be1d-6d94b6b03495",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“one of the challenges with H3R receptor antagonist design” as being the “similarity between the H3 and hERG pharmacophores.” — The histamine H3 receptor as a therapeutic drug target for CNS disorders",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cce-dd3b09fb37ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://pubmed.ncbi.nlm.nih.gov/19429511/; https://pubmed.ncbi.nlm.nih.gov/20716022/",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1fa09aa-842f-472f-8264-9e8660cb1b0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.41,
        "x": 0.52,
        "y": 0.3
      },
      "kind": "title",
      "text": "Same issues even with non-imidazole compounds such as pitolisant",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1986f5be-9b5c-4a25-93a9-97a16e501b8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.38,
        "x": 0.07,
        "y": 0.3
      },
      "kind": "title",
      "text": "Challenges due to similarity of H3 and hERG pharmacophores",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5659acc-a876-4199-ba9b-8133267797ed",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}